Case report of a Quilty lesion within a coronary artery.

The Quilty lesion is the moniker of a lymphoid proliferation that resides predominantly in the endocardium and underlying myocardium within transplanted hearts. It has been described in the endocardium, myocardium, and epicardium. Although its pathogenesis is not understood, it is generally considered that the Quilty lesion is not a manifestation of acute rejection. However, its clinical significance and relation to acute rejection, such as its pathogenesis, are still not completely understood. Immunohistochemical studies distinguish between the cellular infiltrates of Quilty lesions and those associated with acute rejection. We describe, what we believe to be, the first case of a Quilty lesion in an epicardial coronary artery from an 8-year-old girl with congenital heart disease who required retransplantation 25 months after her cardiac transplantation for severe graft coronary artery disease. The lesion consisted of an intramural nodular aggregate of numerous T and B lymphocytes, with fewer macrophages, characteristic of a Quilty lesion.

Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy.

Systemic lymphomas may involve the liver but rarely cause fulminant hepatic failure (FHF). Acute liver failure from primary hepatic lymphoma (PHL) is even less common with most patients succumbing to the sequelae of FHF before the correct diagnosis is made. We report a patient who underwent successful orthotopic liver transplant (OLT) and chemotherapy for FHF secondary to PHL. This previously-well male developed profound coagulopathy and encephalopathy 6 weeks after the onset of jaundice and fatigue. Workup failed to reveal the underlying cause of his liver failure and the patient soon required urgent OLT. Pathologic evaluation of his explanted liver revealed a malignant T-cell rich, large B-cell non-Hodgkin's lymphoma with widespread hepatocellular necrosis. The patient made an excellent clinical recovery and is undergoing CHOP-Rituxan chemotherapy. This scenario demonstrates that lymphoma should be considered in the differential diagnosis of FHF without clear etiology because of the potential for intervention with transplant and chemotherapy.

Myocarditis temporally related to the use of gefitinib (Iressa).

Gefitinib is a new drug that was approved by the US Food and Drug Administration in May 2003 for non-small cell cancer of the lung refractory to first- and second-line therapy. It is regarded as a rather safe drug with common adverse effects that include nausea, vomiting, diarrhea, rash, acne, and dry skin. However, it was reported in Japan to be associated with interstitial pneumonitis (2%-3% of subjects), presumably as a manifestation of a hypersensitivity reaction. The Food and Drug Administration studied this in US patients and found only a 0.3% occurrence and a slightly less than 0.1% mortality due to interstitial pneumonitis. To our knowledge, there has not been an association with fulminant myocarditis or acute myocarditis. We report the case of a 71-year-old man who died as a result of fulminant myocarditis 1 week after starting to take this new class of agent, gefitinib. On the basis of his medical history and our findings, we feel it necessary to consider hypersensitivity myocarditis related to gefitinib the probable cause of death.